Multiple sclerosis (MS) affects almost three million people in the world, and Canada has one of the highest rates of any country. This company is trying to find a way to identify the markers to enhance treatment options for this $23 billion market.
MYND LIFE SCIENCES INC. (CSE: MYND) (OTC: MYNDF) announced that its wholly-owned subsidiary MYND DIAGNOSTICS INC. commenced clinical research on a testing procedure as an aid for diagnosing and monitoring MS utilizing the Company's proprietary anti-inflammatory peptide biomarker.
Validation is planned for the first quarter 2022, and pending those results, a submission for FDA approval could take place as early as second half 2022 to prepare for commercialization and making the MAP Biomarker test available to the public through healthcare practitioners.
MYND is looking to disrupt the global multiple sclerosis therapies market, valued at $22.99 billion in 2018, with a $28 billion projection by 2026,
Markets were trading down, and shares of MYND were also lower in morning trade.
